Therapeutic Action
Antiretroviral, HIV nucleoside reverse transcriptase inhibitor
PDF page 19
Loading InternPractice…
Drug reference
Antiretroviral, HIV nucleoside reverse transcriptase inhibitor
PDF page 19
HIV infection, in combination with other antiretrovirals
PDF page 19
Do not administer to patients with severe hepatic impairment or history of hypersensitivity reaction to abacavir that led to discontinuation of treatment. Administer with caution to patients with hypertension, diabetes, hyperlipidaemia (might increase the risk of coronary disease). May cause: hypersensitivity reactions: fever, rash, gastrointestinal disturbances (nausea, vomiting, diarrhoea, abdominal pain), pharyngitis, cough, dyspnoea, malaise, headache, lethargy, myalgia, arthralgia; lactic acidosis, pancreatitis and hepatic disorders. In all these cases, stop taking abacavir immediately and permanently. Pregnancy: no contra-indication
PDF page 20
Fixed-dose combinations with lamivudine (3TC): 120 mg abacavir/60 mg lamivudine breakable and dispersible tablet 600 mg abacavir/300 mg lamivudine tablet
PDF page 19
The daily dose can be administered once daily or in 2 divided doses. Child 1 month and over and adult: Daily dose Weight 120/60 mg tablet 600/300 mg tablet ABC/3TC ½ tab x 2 3 to < 6 kg 120/60 mg – or 1 tab x 1 ½ tab morning and 1 tab evening 6 to < 10 kg 180/90 mg – or 1 ½ tab x 1 1 tab x 2 10 to < 14 kg 240/120 mg – or 2 tab x 1 1 tab morning and 1 ½ tab evening 14 to < 20 kg 300/150 mg – or 2 ½ tab x 1 1 ½ tab x 2 20 to < 25 kg 360/180 mg – or 3 tab x 1 ≥ 25 kg 600/300 mg – 1 tab x 1
PDF pages 19, 20
Depending on the efficacy and tolerance of abacavir.
PDF page 20
Do not cut, crush or chew the 600/300 mg tablets. Also comes in fixed-dose combination 60 mg abacavir/30 mg lamivudine/5 mg dolutegravir dispersible tablet. Preferably use this formulation when available in children.
PDF page 20
– – Below 25 °C
PDF page 21